Neurogene (NGNE) Revenue (2018 - 2024)

Neurogene's (NGNE) quarterly Revenue came in at $925000.0 in Q2 2024, down 99.91% on a QoQ basis from $1.0 billion in Q3 2019.

Analysis

Neurogene (NGNE) Revenue (2018 - 2024) Analysis & Trends

Neurogene (NGNE) has 3 years of Revenue data on file, last reported at $925000.0 in Q2 2024.

Quarterly Revenue changed N/A year-over-year to $925000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2025 was $925000.0 (changed 0.0% YoY) and the FY2024 annual result came in at $925000.0, changed N/A from the prior year.
Revenue retreated to $925000.0 in Q2 2024, from $1.0 billion in the prior quarter.
In the past five years, Revenue ranged from a high of $925000.0 in Q2 2024 to a low of $925000.0 in Q2 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	1.52 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	145.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	1.71 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	1.29 Bn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	674.14 Mn
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	425.49 Mn
10	Neurogene	864.53 Mn	864.53 Mn	-	-

Historic Data

Download Data